Research at Oslo University Hospital

A combined research effort by scientists at the Weizmann Institute of Science in Israel and researchers at the Netherlands Cancer Institute in Amsterdam and Oslo University Hospital/University of Oslo, Norway, shows exactly how tumors can overcome hurdles that occur when starved for certain building blocks used in protein synthesis.  These results could be exploited for the development of new immunotherapies, as they unravel a completely new class of therapeutic targets that cannot be detected at the genomic (DNA) level. The study was published in Nature Dec 17.
The findings were presented in a full-page story in the major national newspaper VG on January 7th.

Radforsk annually distribute funding to photodynamic therapy and photochemical internalization (PDT/PCI) related research.
Application deadline for 2021 is January 15th.
Please note that one project will be chosen to receive a larger project grant on 1,25 MNOK per year for 3 years, in this application round.
All Oslo University Hospital employees can apply for funding.

Read complete announcement at the Radforsk home page

On this web page you will find an overview over planned and ongoing clinical trials and other research projects at Oslo University Hospital related to COVID-19 and SARS CoV-2 infection. The information has been retrieved from applications to the regional ethics committee, the Norwegian Research Council, other funding sources, or directly from the researchers behind the projects.
An updated list of publications related to COVID-19 research at Oslo University Hospital can be found here.

The Syljuåsen Lab at the Department of Radiation Biology, Institute for Cancer Research reports new basic knowledge about factors underlying replication stress in cancer cells.
Replication stress can drive cancer development and may also be exploited in therapy. Understanding the molecular mechanisms underlying replication stress is therefore important. Transcription-replication conflicts are a major source of replication stress. The new findings by Landsverk et al. suggest that proper dephosphorylation of RNA polymerase 2, the main mediator of the transcription of DNA into mRNA, is needed to prevent such conflicts.

There is much focus upon using nanoparticles for cancer therapy, including discussions about how these particles are transported across the endothelial cell layer before being taken up by tumor cells.
Tore Skotland and Kirsten Sandvig from the "Intracellular transport" research group at the Department of Molecular Cell Biology at the Institute for Cancer Research recently discussed these issues in an article published in Nano Today (impact factor 16.9).

The OMEMI trial (OMega-3 fatty acids in Elderly patients with Myocardial Infarction) conducted from Center for Clinical Heart Research (CCHR), Department of Cardiology, OUS Ullevål, has achieved international publicity.

The study was presented as a "Late Breaking Trial" at the American Heart Association (AHA) Scientific Session  2020, with simultaneous publication in the prestigious journal Circulation.

Anita Sveen (39) – senior researcher and project group leader at Institute for Cancer Research – was on December 16th awarded the prize Researcher-of-the-Year from the leadership at ICR for her outstanding scientific contributions. The award of 100 000 NOK is financed by the Radium Hospital Foundation (Radiumhospitalets legater) and is a personal scholarship for stimulating further excellence in research. 

The Malmberg Lab at the Department of Cancer Immunology, Institute for Cancer Research, OUH and the Institute for Clinical Medicine, UiO, reports a systems-level immune profiling in patients with diffuse large-B cell lymphoma (DLBCL). The paper is published online in Med, a new flagship medical journal from Cell Press. 
DLBCL is the most common form of lymphoma. Despite advances in treatment, there are still large differences in outcome that are not fully explained by current clinical variables.